国际医药卫生导报
國際醫藥衛生導報
국제의약위생도보
INTERNATIONAL MEDICINE & HEALTH GUIDANCE NEWS
2011年
11期
1351-1353
,共3页
糖尿病%冠心病%辛伐他汀%血管内皮功能%血脂%血糖
糖尿病%冠心病%辛伐他汀%血管內皮功能%血脂%血糖
당뇨병%관심병%신벌타정%혈관내피공능%혈지%혈당
Diabetes mellitus%Coronary heart disease%Simvastatin%Vascular endothelial function%Blood lipids%Blood sugar
目的 观察辛伐他汀治疗糖尿病合并冠心病的临床疗效.方法 选择47例糖尿病合并冠心病患者,均给予口服辛伐他汀20mg/次,1天1次,连续治疗12周,治疗前后均检测患者血糖、血脂、血浆一氧化氮(NO)与内皮索(ET)水平以及血清定粉样蛋白A(A-SAA),并测定血管内皮细胞的功能.结果 47例患者经过12周的治疗,血脂和肱动脉内皮依赖性舒张功能显著改善,ET水平明显降低,NO明显升高,A-SAA水平降低,与治疗前比较差异均有统计学意义(P<0.05,P<0.01).结论 辛伐他汀通过降脂和平衡NO/ET的比值等途径保护内皮功能,通过降低A-SAA水平可以抵抗动脉粥样硬化的作用.
目的 觀察辛伐他汀治療糖尿病閤併冠心病的臨床療效.方法 選擇47例糖尿病閤併冠心病患者,均給予口服辛伐他汀20mg/次,1天1次,連續治療12週,治療前後均檢測患者血糖、血脂、血漿一氧化氮(NO)與內皮索(ET)水平以及血清定粉樣蛋白A(A-SAA),併測定血管內皮細胞的功能.結果 47例患者經過12週的治療,血脂和肱動脈內皮依賴性舒張功能顯著改善,ET水平明顯降低,NO明顯升高,A-SAA水平降低,與治療前比較差異均有統計學意義(P<0.05,P<0.01).結論 辛伐他汀通過降脂和平衡NO/ET的比值等途徑保護內皮功能,通過降低A-SAA水平可以牴抗動脈粥樣硬化的作用.
목적 관찰신벌타정치료당뇨병합병관심병적림상료효.방법 선택47례당뇨병합병관심병환자,균급여구복신벌타정20mg/차,1천1차,련속치료12주,치료전후균검측환자혈당、혈지、혈장일양화담(NO)여내피색(ET)수평이급혈청정분양단백A(A-SAA),병측정혈관내피세포적공능.결과 47례환자경과12주적치료,혈지화굉동맥내피의뢰성서장공능현저개선,ET수평명현강저,NO명현승고,A-SAA수평강저,여치료전비교차이균유통계학의의(P<0.05,P<0.01).결론 신벌타정통과강지화평형NO/ET적비치등도경보호내피공능,통과강저A-SAA수평가이저항동맥죽양경화적작용.
Objective To observe the efficacy of simvastatin for diabetes mellitus with coronary heart disease. Methods 47 diabetic patients with coronary heart disease patients were chose to treat with oral simvastatin of 20mg once daily for 12 weeks. Before and after treatment, blood levels of sugar, lipids, nitric oxide( NO ), endothelin, and serum amyloid A protein( SAA )were detected, so was the function of vascular endothelial cells. Results After a 12-week therapy, levels of lipids and brachial arterial endothelium-dependent vasodilation were markedly improved, levels of ET and SAA declined and NO level elevated, with a statistical difference ( P < 0.05 and P < 0.01 ). Conclusions Simvastatin can protect endothelial function by reducing lipid levels and balancing the NO/ET ratio and play an anti-atherosclerotic role by lowering SAA levels.